Original Article
Journal of Cerebral Blood Flow & Metabolism (2000) 20, 1587–1603; doi:10.1097/00004647-200011000-00009
Similarity and Robustness of PET and SPECT Binding Parameters for Benzodiazepine Receptors
Supported by the Swiss National Science Foundation (n° 32–52 894.97) and in part by the Société Académique of Geneva.
Philippe Millet*, Christophe Graf*, Alfred Buck†, Bernard Walder£, Gerrit Westera†, Claudia Broggini*, Michele Arigoni†, Daniel Slosman§, Constantin Bouras¶ and Vicente Ibáñez*
- *Department of Psychiatry, Neuroimaging Unit, University Hospital of Geneva (HUG), Geneva, Switzerland
- †University of Zurich Hospital, Zurich, Switzerland
- £Division of Anesthesiology, Morphology Unit, HUG, Switzerland
- §Department of Nuclear Medicine, Morphology Unit, HUG, Switzerland
- ¶Department of Psychiatry, Morphology Unit, HUG, Switzerland
Correspondence: Philippe Millet, Hopitaux Universitaires de Genéve, Unité de Neuroimagerie Psychiatrique, 2, chemin du Petit-Bel-Air CH-1225 Chêne-Bourg, Genéve, Suisse.
Received 17 April 2000; Revised 19 July 2000; Accepted 19 July 2000.
Abstract
The single photon emission computed tomography (SPECT) radiotracer [123I]iomazenil is used to assess benzodiazepine receptor binding parameters. These measurements are relative indices of benzodiazepine receptor concentration (B´max). To evaluate the ability of such indices in accurately accessing the B´max the authors compared them with absolute values of B´max, measured using positron emission tomography (PET). The authors performed SPECT, PET, and magnetic resonance imaging (MRI) studies on a group composed of seven subjects. For SPECT studies, the authors administered a single injection of [123I]iomazenil and estimated the total and specific distribution volumes (DVT SPECT, DVS SPECT) and the binding potential (BP) using unconstrained (BPSPECT) and constrained (BPC SPECT) compartmental models. For PET studies, the authors used a multiinjection approach with [11C]flumazenil and unlabeled flumazenil to estimate absolute values of receptor concentration, B´max, and some other binding parameters. The authors studied the correlation of different binding parameters with B´max. To study the robustness of the binding parameter measurements at the pixel level, the authors applied a wavelet-based filter to improve signal-to-noise ratio of time-concentration curves, and the calculated kinetic parameters were used to build up parametric images. For PET data, the B´max and the DVPET were highly correlated (r = 0.988). This confirms that it is possible to use the DVPET to access benzodiazepine receptor density. For SPECT data, the correlation between DVSPECT estimated using a two-and three-compartment model was also high (r = 0.999). The DVT SPECT and BPC SPECT parameters estimated with a constrained three-compartment model or the DVT"SPECT parameter estimated with a two-compartment model were also highly correlated to the B´max parameter estimated with PET. Finally, the robustness of the binding parameters allowed the authors to build pixel-by-pixel parametric images using SPECT data.
Keywords:
[123I]iomazenil, [11C]flumazenil, PET, SPECT, Benzodiazepine receptors, Parametric images
Abbreviations:
B´max, receptor concentration; BP, binding potential; BPC, binding potential estimated with a constrained three-compartmental model; DA, delayed-activity; DV, distribution volume; DVf+ns, free and nonspecific distribution volume; DVs, specific distribution volume; DVT, total distribution volume estimated with a three-compartment model; DVT", total distribution volume estimated with a constrained two-compartment model; DVTC, total distribution volume estimated with a constrained three-compartmental model; FMZ, flumazenil; GABA, gamma-aminobutyric acid; IMZ, iomazenil; Kd, ligand affinity; MRI, magnetic resonance imaging; PET, positron emission tomography; ROI, region of interest; SPECT, single photon emission computed tomography

